重组人促红素联合蔗糖铁治疗维持性血液透析贫血患者的效果观察

Effect observation of recombinant human erythropoietin combined with iron sucrose in treatment of anemia patients with maintenance hemodialysis

目的探讨重组人促红素联合蔗糖铁治疗维持性血液透析贫血患者的临床效果。方法选取维持性血液透析贫血患者64例,随机分为对照组和观察组,每组32例。对照组采用蔗糖铁治疗,观察组在对照组基础上加用重组人促红素治疗。2组均连续治疗8周,比较2组临床效果,治疗前后红细胞参数、铁代谢指标、炎症指标以及不良反应发生情况。结果观察组总有效率为84.38%,高于对照组的65.63%,差异有统计学意义(P<0.05)。2组治疗后红细胞压积(Hct)、血红蛋白(Hb)、转铁蛋白饱和度(TSAT)及铁蛋白(SF)水平均高于治疗前,且观察组上述指标均高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)及超敏C反应蛋白(hs-CRP)水平均低于对照组,差异有统计学意义(P<0.05)。2组治疗期间均未发生明显的不良反应。结论重组人促红素联合蔗糖铁治疗维持性血液透析贫血患者可获得显著的治疗效果,有效改善患者铁代谢情况,促进红细胞代谢,降低机体炎症因子水平。

Objective To investigate the clinical effect of recombinant human erythropoietin combined with iron sucrose in treatment of anemia patients with maintenance hemodialysis. Methods Totally 64 anemia patients with maintenance hemodialysis were selected and randomly divided into control group and observation group,with 32 cases in each group. The control group was treated with iron sucrose,while the observation group was treated with recombinant human erythropoietin on the basis of the control group. Both groups were treated for 8 weeks. The clinical effect,the red blood cell parameters,iron metabolism indexes and inflammation indexes before and after treatment as well as adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 84. 38%,which was significantly higher than 65. 63% of the control group (P <0. 05). After treatment,levels of hematocrit (Hct),hemoglobin (Hb),transferrin saturation (TSAT) and ferritin (SF) in both groups were significantly higher than those before treatment,and the indexes mentioned above in the observation group were significantly higher than those in the control group (P < 0. 05). After treatment,the levels of tumor necrosis factor-α (TNF-α),interleukin-6 (IL-6) and high sensitivity C-reactive protein (hs-CRP) in the observation group were significantly lower than those in the control group (P < 0. 05). No obvious adverse reactions were found in both groups during the treatment. Conclusion Recombinant human erythropoietin combined with iron sucrose is effective in treatment of anemia patients with maintenance hemodialysis,which can improve the iron metabolism of patients,promote the metabolism of red blood cells,and reduce the levels of inflammatory factors.